Merck and Artios Pharma announce oncology collaboration

The agreement does not include Artios’s lead programmes, Polθ and ATR inhibitors, for which it will retain all rights

Merck KGaA and Artios Pharma Limited have announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.

Under the terms of the agreement, the companies will use Artios’s proprietary nuclease targeting discovery platform to identify multiple synthetic lethal targets for precision oncology drug candidates. During this joint research collaboration, Merck will contribute expertise and resources in the field of DDR and will have exclusive worldwide rights to develop and commercialise selected therapeutics discovered under the collaboration.

Nucleases are critical enzymes involved in the maintenance of genomic integrity. Cancer cells are dependent on nucleases for their survival in response to DNA damage. Also, in certain cancers which exhibit mutations in DNA damage response pathways, inhibiting key nucleases can lead to selective cancer cell killing i.e. synthetic lethality.

As part of the agreement, Artios will receive a payment of $30m in the form of an up-front and near-term payments. If Merck chooses to exercise the option, subject to double-digit option fees, Artios will be eligible to receive up to $860m per target, in addition to up to double digit royalty payments on net sales of each product commercialised by Merck.

Subject to certain conditions, Artios has opt-in rights for joint development and commercialisation for the programmes.

“Our platform has the potential to revolutionize targeted treatment in cancer and deliver on the promise of precision medicine. This collaboration will leverage the potential of our unique discovery platform of novel DNA repair nuclease inhibitors and targets that we have been developing. The partnership puts us in an exceptional position to focus internal efforts on our leading portfolio of assets which includes a small-molecule ATR inhibitor and a Polθ programme, both in candidate IND evaluation,” said Niall Martin, CEO at Artios Pharma.

“Targeting DNA damage response has the potential to provide an important therapeutic option for many patients in need of new treatments. We are excited about working with Artios to develop novel precision oncology medicines as we move towards changing the current paradigm in cancer treatment. This collaboration further strengthens our leadership and expertise in the field and discovery of DDR inhibitors and complements our multiple innovative assets currently being evaluated in several Phase I and Phase II clinical studies,” said Andree Blaukat, SVP and Head Translational Innovation Platform Oncology & Immuno-Oncology, at Merck KGaA, Darmstadt, Germany.

Companies